SCHEMBL2727482

SCHEMBL2727482

O=C(O)C(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO

nearest known ligand 0.95

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.95
LMNA P02545 2/20 0.64
TDP1 Q9NUW8 1/20 0.60
USP2 O75604 1/20 0.58
SLCO1B1 Q9Y6L6 1/20 0.58
L3MBTL1 Q9Y468 1/20 0.55
TSHR P16473 2/20 0.50
CYP2C9 P11712 1/20 0.50
OR51E2 Q9H255 1/20 0.42
KDM4E B2RXH2 2/20 0.39
PGD P52209 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3089 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL7148337 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL9227895 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL9551477 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL3090 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL9232100 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL9227913 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL9232096 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL21580532 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1
SCHEMBL9228526 1.00 PDE4A (0.95) PDE4ALMNATDP1USP2SLCO1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114787368-A Sorbitan esters and enzymatic process for their preparation 赢创运营有限公司 2022-07-22 CN claimed
WO-2022049604-A1 PROCESS FOR PREPARING REVEFENACIN AND INTERMEDIATES THEROF CIPLA LIMITED (IN) 2022-03-10 WO claimed
CN-106476379-B A kind of heat-insulated antifog film of vehicle glass 东莞市联洲知识产权运营管理有限公司 2018-08-17 CN claimed
CN-106476379-A A kind of heat-insulated antifog film of vehicle glass 东莞市联洲知识产权运营管理有限公司 2017-03-08 CN claimed
CN-106281096-A A kind of environment friendly heat resistant rupture pressure disc 东莞市联洲知识产权运营管理有限公司 2017-01-04 CN claimed
CN-103003405-B Aqueous alkaline cleaning compositions and methods of use thereof BASF SE (DE) 2016-04-13 CN claimed
CN-103003405-A Aqueous alkaline cleaning compositions and methods of use thereof BASF SE 2013-03-27 CN claimed
US-4724099-A REACTION PRODUCT OF ESTER OF A POLYHYDRIC ALCOHOL AND A BORON-CONTAINING HETEROCYCLIC COMPOUND; EXTREME PRESSURE LUBRICANTS; AUTOMATIC TRANSMISSION FLUIDS UNION OIL COMPANY OF CALIFORNIA (US) 1988-02-09 US claimed
EP-3515571-B1 ISOTOPIC COMPOSITIONS BOTANICAL WATER TECH IP LTD (GB) 2026-01-07 EP disclosed
EP-4655387-A1 ROOM-TEMPERATURE-STABLE CULTURE MEDIA AND SUPPLEMENTS Life Technologies Corporation (US) 2025-12-03 EP disclosed
US-20250345435-A1 ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF FENNEC PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
US-20250346643-A1 TROPOMYOSIN KINASE RECEPTOR (TRK) LIGANDS AS THERAPEUTICS TO SUPPORT LIVER REGENERATION UNIV VANDERBILT (US) 2025-11-13 US disclosed
EP-4591939-A2 FORMULATIONS OF SODIUM THIOSULFATE Fennec Pharmaceuticals, Inc. (US) 2025-07-30 EP disclosed
EP-4578506-A2 FORMULATIONS OF ANHYDROUS SODIUM THIOSULFATE Fennec Pharmaceuticals, Inc. (US) 2025-07-02 EP disclosed
CN-103003405-B Aqueous alkaline cleaning compositions and methods of use thereof BASF SE (DE) 2016-04-13 CN disclosed
CN-103003405-B Aqueous alkaline cleaning compositions and methods of use thereof BASF SE (DE) 2016-04-13 CN disclosed
CN-103003405-A Aqueous alkaline cleaning compositions and methods of use thereof BASF SE 2013-03-27 CN disclosed
WO-2012058298-A1 BIOMARKERS OF REDUCED INSULIN ACTION MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2012-05-03 WO disclosed
CN-1211287-C Method for producing suspensions and powders of indium tin oxide and use thereof INST NEW MATERIALEN GEM GMBH (DE) 2005-07-20 CN disclosed
CN-1314871-A Method for producing suspensions and powders based on indium tin oxide and the use thereof INST NEUE MATERIALEN GEM GMBH (DE) 2001-09-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250346643-A1 TROPOMYOSIN KINASE RECEPTOR (TRK) LIGANDS AS THERAPEUTICS TO SUPPORT LIVER REGENERATION HGF, HDGF, NTRK2 PDE4A 1558/4885LMNA 2803/4885TDP1 1903/4885
US-20250345435-A1 ANHYDROUS SODIUM THIOSULFATE AND FORMULATIONS THEREOF TST, MPST, TPMT PDE4A 4315/4885LMNA 4594/4885TDP1 362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.